Emerging Drug Developer: Ambit Biosciences

Emerging Drug Developer: Ambit Biosciences

Ambit Biosciences has taken another important step forward. In the middle of last month, CEO Scott Salka announced that it had garnered about $50 million in its fourth round. That money should be enough to get the company through 2009, a key transition period for Ambit. "We're expecting at least clinical proof of concept and completion of that milestone with one compound by the end of '09." Salka tells FierceBiotech, which named Ambit a Fierce 15 company in 2006. Article

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.